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Available online 27 February 2016The FluoroSpot assay, a variant of ELISpot utilizingﬂuorescent detection, has so far beenused primarily for assess-
ment of T cells, where simultaneous detection of several cytokines has allowed a more qualitative analysis of
functionally distinct T cells. The potential to measure multiple analytes also presents several advantages when
analyzing B cells. Our aim was to develop a B-cell FluoroSpot assay adaptable to studies of a variety of antigens.
The assay utilizes anti-IgG antibodies immobilized in 96-well ﬁlter membrane plates. During cell culture, IgG
antibodies secreted by antibody-secreting cells (ASCs) are captured in the vicinity of each of these cells and
the speciﬁcity of single ASCs is deﬁned using antigens for detection. The antigenswere labeledwith biotin or pep-
tide tags enabling secondary detection with ﬂuorophore-conjugated streptavidin or tag-speciﬁc antibodies. The
assay, utilizing up to four different tag systems and ﬂuorophores simultaneously, was evaluated using hybrid-
omas and immunized splenocytes as ASCs. Assay variants were developed that could: i) identify multiple ASCs
with different antigen speciﬁcities; ii) detect ASCs showing cross-reactivity with different but related antigens;
and iii) deﬁne the antigen-speciﬁcity and, by including anti-IgG subclass detection reagents, simultaneously de-
termine the IgG subclass of antibodies secreted by ASCs. As demonstrated here, the B-cell FluoroSpot assay using
tag-based detection systems provides a versatile and powerful tool to investigate antibody responses by individ-
ual cells that can be readily adapted to studies of a variety of antigen-speciﬁc ASCs.






Many techniques are available for the analysis of antibody reactivity
and speciﬁcity but few assays provide a simple method to analyze
antigen-speciﬁc antibody responses at the level of the individual cell.
By analyzing antibody-secreting cells (ASCs) at the single-cell level, it
is possible to obtain a broader view of humoral immunity and to follow
the progress of antigen-speciﬁc responses and the development of im-
munological memory (Jahnmatz et al., 2013). Studies of the speciﬁcity
and cross-reactivity shown by single B cells and the antibodies they se-
crete are highly relevant in various areas of immunology, not least for
the development of vaccines against, for example, inﬂuenza, HIV, andne serum albumin; DENV, den-
; FCS, fetal calf serum; FITC,
erferon-gamma; IL, interleukin;
body; PBS, phosphate-buffered
ment of Medicine Solna, SE-171
. This is an open access article undermalaria where broadly cross-reactive antibodies recognizing variable
antigens expressed by different strains of pathogens are desired
(Ellebedy et al., 2014; Kennedy et al., 2002; Williams et al., 2015).
Methods used for analyzing the antigen speciﬁcity of antibodies
from a single ASC are often laborious and time-consuming. By
Epstein–Barr virus transformation, human B cells can be immortalized
and used to produce monoclonal antibodies (mAbs) (Steinitz et al.,
1980). Another approach is to use ﬂow cytometry-based cell sorting
for the isolation of B cells followed by cloning of their immunoglobulin
(Ig) genes and recombinant expression of antibodies (Tiller et al., 2008).
Suchmethods have been used for example to study the development of
neutralizing antibodies from memory B cells against HIV (Scheid et al.,
2009). A recently described method is based on imprinting wells in mi-
croarray chips in which B cells can be seeded individually and cultured;
subsequently minute amounts of clonal antibodies in the supernatants
can be analyzed without the need to immortalize the ASCs or express
antibodies recombinantly (Jin et al., 2009).
The ELISpot assay was ﬁrst described in 1983 as a simple and effec-
tive tool to analyze single B cells secreting antibodies (Czerkinsky
et al., 1983), and later also for the analysis of T cells secreting cytokinesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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30 years the B-cell ELISpot assay has beenwidely used for the detection
and enumeration of single antigen-speciﬁc plasmablasts or in vitro-
activated memory B cells (Giannini et al., 2006; Tangye et al., 2003). Al-
though the B-cell ELISpot assay offers a versatile, robust, and highly sen-
sitive method to analyze single antigen-speciﬁc ASCs (Currier et al.,
2002), it is limited to the analysis of one antigen at a time. In 2003,
Gazagne et al. described a dual FluoroSpot assay that facilitated detec-
tion of various subpopulations of human cytokine-secreting T cells
simultaneously (Gazagne et al., 2003), and recently a FluoroSpot assay
was developed for the simultaneous detection of T cells producing
human interferon-gamma (IFN-γ), interleukin (IL)-17A, and/or IL-22
using three different ﬂuorophores (Dillenbeck et al., 2014). The princi-
ple of FluoroSpot is similar to that of ELISpot but, instead of using a pre-
cipitating substrate that forms spots on the membrane, FluoroSpot
utilizes ﬂuorophore-conjugated detection reagents. The ﬂuorophores
emit light at speciﬁc wavelengths when excited by a light source deliv-
ered by the FluoroSpot reader. Using a reader equipped with different
wavelength-speciﬁc ﬁlters, each ﬂuorophore is analyzed separately.
The reader captures separate images for each ﬂuorophore and subse-
quently combines the images digitally enabling multiplex analysis
and/or detection of co-positioned spots (Janetzki et al., 2014).
FluoroSpot assays have also been adapted for the analysis of B cells
secreting antigen-speciﬁc IgG and IgA antibodies against inﬂuenza anti-
gen using a single antigen immobilized on a solid phase (Weinberg
et al., 2015). The potential to analyze multiple antigens in one well
was suggested by the ﬁndings of a study in which a reversed antigen-
speciﬁc ELISpot assay was developed (Dosenovic et al., 2009). In the re-
versed assay, anti-IgG antibodies immobilized on the solid phase were
allowed to capture ASC-derived antibodies that in turn were detected
with a single biotinylated antigen. Using a similar approach, but with
multiple antigens, Hadjilaou et al. recently described a B-cell FluoroSpot
assay capable of detecting and analyzing ASC reactivity with four sero-
types of dengue virus (DENV) virions (Hadjilaou et al., 2015). Antibod-
ies secreted by B cells were captured by anti-IgG antibodies on a ﬁlter
plate, then DENV virions representing each of the four serotypes were
added. Antibodies from DENV-speciﬁc ASCs, having captured the vi-
rions, were then detected using four ﬂuorophore-conjugated DENV
serotype-speciﬁc mAbs and hence B-cell reactivity with single or multi-
ple DENV serotypes could be deﬁned.
In the present study, we designed a FluoroSpot assay capable of ana-
lyzing ASC reactivity with multiple antigens, without the limitation of a
given set of antigens. In contrast to the DENV serotype FluoroSpot
which utilizes antigen-speciﬁc mAbs for detection (i.e. antigen speciﬁc
in the sense that the detection mAb is directed against the same antigen
that the ASC recognizes) and hence is conﬁned to studies of DENV-Fig. 1.Overview of the different FluoroSpot assay formats evaluated. Immobilized anti-mouse I
The ASC-derived antibodies were subsequently allowed to bind antigens tagged with either pe
peptide-speciﬁc antibodies or streptavidin (SA), the location of an ASC with a given speciﬁcity
ASC reactive with four different antigens could be detected using four different anti-tag reage
cross-reactivity with two antigens could be identiﬁed since spots of two different colors wou
C) Simultaneous detection of the antigen-speciﬁcity and the Ig isotype/subclass of ASC-deriv
determined by addition of an isotype/subclass-speciﬁc antibody labeled with another ﬂuorophspeciﬁc ASCs (Hadjilaou et al., 2015), our assay was based on a different
approach. Antigens were either biotinylated or recombinantly produced
with different peptide tags allowing detection with ﬂuorophore-
conjugated streptavidin (SA) and peptide tag-speciﬁc mAbs, respective-
ly, thus facilitating the use of themethod for virtually any antigen labeled
with these tags. To demonstrate the functionality of the assay, we evalu-
ated its capacity to simultaneously detect ASCs producing speciﬁc
antibodies against four different antigens. The assaywas also used to dis-
tinguish between ASCs that did and did not display cross-reactivity with
variants of an antigen. Finally, we showed that this FluoroSpot assay
could be used to simultaneously determine the isotype/subclass and an-
tigen speciﬁcity of antibodies from individual ASCs. Schematic illustra-
tions of the different assay variants are shown in Fig. 1.
2. Materials and methods
2.1. Mouse splenocytes
A female BALB/c mouse was housed at Karolinska Institutet,
Stockholm, Sweden and handled in accordance with the guidelines of
the Swedish Ethical Committee for Animal Protection. The mouse was
immunized subcutaneously on three occasions with 75 μg/mL recombi-
nant cat IFN-γ (Mabtech, Nacka Strand, Sweden) and 25 μg/mL G3-
VAXSAP adjuvant (MOREINX AB, Uppsala, Sweden) in 200 μL sterile
phosphate-buffered saline (PBS). Four days prior to splenectomy, the
mouse was boosted intraperitoneally with cat IFN-γ in PBS. The spleen
was passed through a cell strainer (BD/Falcon, Becton Drive Franklin
Lakes, NJ, USA) in order to separate splenocytes from tissue. Splenocytes
were washed in Dulbecco's modiﬁed Eagle's medium (DMEM) supple-
mented with 100 U/mL penicillin and 100 μg/mL streptomycin (all
from Invitrogen Life Technologies, Carlsbad, CA, USA) and cell concen-
tration and viability (N90%) were assessed using a Guava ViaCount
assay (Guava Technologies, Hayward, CA, USA). Next, splenocytes
were suspended in DMEM supplemented with 20% heat-inactivated
fetal calf serum (FCS) (Invitrogen Life Technologies), 10% dimethyl sulf-
oxide (Sigma-Aldrich, Saint Louis, MO, USA), 100 U/mL penicillin, and
100 μg/mL streptomycin and frozen in cryogenic vials at−80 °C and
then stored in liquid nitrogen until required for analyses.
2.2. MAbs against peptide tags
A synthetic peptide CPDYRPYDWASPDYRD (designated WASP), de-
signed to comprise a B-cell epitope, was conjugated to keyhole limpet
hemocyanin (KLH) using the Imject™Maleimide-Activated mcKLH kit
(Thermo Fisher Scientiﬁc, Rockford, IL, USA) according to the protocol
described by the manufacturer. A mAb against WASP was generatedgG antibodies were used to capture antibodies secreted by antibody-secreting cells (ASCs).
ptides or biotin in order to determine the speciﬁcity of ASC. By using ﬂuorescently labeled
could be determined. A) By adding four different antigens, each labeled with a unique tag,
nts. B) By adding two related antigens with similar amino acid sequences, ASC displaying
ld co-localize. Non-cross-reactive ASC would only bind one of the antigens (not shown).
ed antibodies. Antigen speciﬁcity was identiﬁed as in A) and the Ig isotype/subclass was
ore.
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were immunized as above with 100 μg/mL WASP-KLH and 60 μg/mL
AbISCO-100 adjuvant (Isconova, Uppsala, Sweden) in 200 μL PBS. In
order to obtain Ig-secreting hybridomas, splenocytes were prepared as
above and fused with the non-Ig producing mouse myeloma cell line
Sp2/0 (Shulman et al., 1978). Supernatants from hybridoma cultures
were screened in an ELISA to analyze reactivitywithWASP peptide con-
jugated to bovine serum albumin (BSA) using the Imject™Maleimide-
Activated BSA system (Thermo Fisher Scientiﬁc). After selection of a hy-
bridoma producing the mAb with the best reactivity against WASP, the
hybridomawas cultured andmAbswere puriﬁed from the supernatant.
PuriﬁedmAbswere then labeledwith Fluorescein isothiocyanate (FITC)
(Thermo Fisher Scientiﬁc) according to themanufacturer's instructions.
In addition to mAb anti-WASP, SA and two peptide-reactive mAbs spe-
ciﬁc for either BAM tag peptide DAEFRHDSGY (mAb bm-AbetaN, here
termed anti-BAM) or GAL tag peptide YPGQAPPGAYPGQAPPGA (mAb
Gal-3, here termed anti-GAL) were used as detection reagents (product
codes 3740–5 and 3720–3, respectively; Mabtech). In addition to FITC
that absorbs and emits light at a wavelength of 490/520 nm, detection
reagents were conjugated with ﬂuorophores absorbing and emitting
light at 350/470, 550/570 and 640/660 nm (Mabtech). Detection re-
agents were used in combination with different ﬂuorophores as de-
scribed in the text. The ﬂuorophore used is speciﬁed by its excitation
wavelength.
2.3. Mouse hybridomas used in FluoroSpot assay evaluations
Hybridomas used asmodel ASCs for the evaluation of FluoroSpot as-
says were previously developed at Mabtech for use in various cytokine
immunoassays. Before FluoroSpot analysis, frozen hybridomas were
rapidly thawed at 37 °C and washed twice in DMEM supplemented
with 10% heat-inactivated FCS, 100 U/mL penicillin, and 100 μg/mL
streptomycin (culture medium). Cells were seeded at 500,000 cells/
mL in T25 cell culture ﬂasks (Costar, Corning, NY, USA) and cultivated
in culture medium at 37 °C and 5% CO2. Before use in the FluoroSpot
assay, cells were counted and viability determined (N90%) using the
Guava ViaCount assay.
2.4. Antigens used in FluoroSpot
Several antigens used in the FluoroSpot assays were produced
recombinantly based on the following protein sequences: human IFN-
γ, UniProt accession number P01579; dog IFN-γ, P42161; woodchuck
IFN-γ, O35735; cow IFN-γ, P07353; sooty mangabey IL-2, P46649;
rhesus macaque IL-2, P68291; and human IL-2, P60568. The peptide
tags BAM, WASP, or GAL were recombinantly added at the N-terminus
of IFN-γ and the C-terminus of IL-2 to allow speciﬁc detection of the an-
tigen using anti-tag mAbs. The mouse IgG kappa leader sequence
(METDTLLLWVLLLWVPGSTGD) was used to facilitate protein secretion.
Synthesis and cloning of gene sequences into plasmid pcDNA3.1/
Zeo(−) were performed by GeneScript (Piscataway, NJ, USA). Transient
transfection was performed using HEK293T/17 cells (American Type
Culture Collection, Manassas, VA, USA), as previously described
(Areström et al., 2012). Cell supernatants were harvested after 6 days
and stored at−20 °C. Protein expression was veriﬁed by western blot
utilizing anti-tag mAbs (data not shown). Recombinant human IFN-γ
and IL-2 (Peprotech, Rocky Hill, NJ, USA), bovine IFN-γ (Thermo Fisher
Scientiﬁc), and cat IFN-γ (RnD Systems,Minneapolis, MN,USA)were bi-
otinylated using long-chain biotinyl-N-hydroxysuccinimide ester sul-
fonic acid (Thermo Fisher Scientiﬁc) according to the manufacturer's
instructions.
2.5. Analysis of cross-reactive anti-human IL-2 mAbs by ELISA
Cross-reactivity of anti-human IL-2 mAbs MT2A91 (product code
3445–1; Mabtech) and MT8G10 (product code 3445–6; Mabtech)with IL-2 from different species was analyzed in an ELISA as previously
described (Areström et al., 2012). Brieﬂy, mAbswere coated onto plates
separately and allowed to bind serial dilutions of recombinant human
IL-2–biotin, sooty mangabey IL-2–BAM, and rhesus macaque IL-2–
BAM, and then detected with SA–enzyme or biotinylated anti-BAM
mAb and SA–enzyme.
2.6. B-cell FluoroSpot assay
Low ﬂuorescent 96-well polyvinylidene ﬂuoride plates (catalog no.
S5EJ104I07; Millipore, Bedford, MA, USA) were pre-wetted with 15 μL
35% ethanol for no more than 1 min, immediately followed by washing
with sterile water ﬁve times (200 μL/well). Next, 100 μL polyclonal goat
anti-mouse IgG (product code 3825;Mabtech) capture antibody diluted
to 15 μg/mL in sterile PBSwas added towells and incubated at 4 °C over-
night. The following day, the plates were washed ﬁve times with sterile
PBS (200 μL/well), and blockedwith 200 μL/well culturemedium for 1 h.
The culturemediumused for blockingwas then replaced by 100 μL/well
fresh medium containing either a single hybridoma, a combination of
hybridoma clones or spleen cells added in triplicate wells. Cells were in-
cubated overnight at 37 °C and 5% CO2, and removed by washing the
plates ﬁve times with PBS (200 μL/well) in an automated ELISA washer.
Filteredmouse serum (200 μL/well; Innovative Research, Novi, MI, USA)
was then added, diluted 1:5 in PBS, and plates were incubated for 2 h at
room temperature (RT). The mouse serum was added to block coating
antibodies from subsequently binding anti-tag detection mAbs. Plates
were then washed again as previously described, followed by addition
of 100 μL/well biotinylated antigen and/or peptide-tagged antigen in su-
pernatant from transfected cells diluted in PBSwith 0.1% BSA (PBS/BSA).
The optimal concentration of each antigen was deﬁned by testing serial
dilutions in pilot tests (data not shown). Plateswere incubated for 2 h at
RT, and then washed as described above. Next, ﬂuorophore-conjugated
detection anti-tag mAbs or SA diluted in PBS/BSA (100 μL/well) were
added separately or in combinations and plates were incubated for 1 h
at RT. Then plates were washed as above and subsequently incubated
with 50 μL/well ﬂuorescent enhancer for 15 min at RT. The enhancer
was removed thoroughly, theplate underdrain discarded, and the plates
were left to dry protected from light. In experiments simultaneously
determining antigen speciﬁcity and IgG subclass of antibodies from hy-
bridoma cells, rat mAb MT24 anti-mouse Ig kappa chain (product code
3875–3; Mabtech) was used for coating. After incubation of hybridoma
cells, ﬂuorophore-conjugated rat mAbs speciﬁc for mouse IgG1
(MG1–490) or IgG2a (MG2a–550 (product codes 3821–3 and 3822–3,
respectively; Mabtech) at 1 μg/mL were added. The wells were blocked
withmouse serum and then tagged antigenswere sequentially incubat-
ed with anti-tag detection reagents. Plates were analyzed using an
ELISpot/FluoroSpot reader system (iSpot Spectrum, AID, Strassberg,
Germany), with software version 7.0 (build 14,790), in which ﬂuores-
cent spots were counted utilizing separate wavelength-speciﬁc ﬁlters.
Filters used were for DAPI, FITC, Cy3 and Cy5 in order to detect
ﬂuorophores absorbing and emitting light at 350/470, 490/520, 550/
570 and 640/660 nm, respectively. Camera settings (exposure and
gain) were adapted for each ﬁlter to obtain high-quality spot images
and prevent over- or under-exposure. The use of ﬂuorophores with dis-
tinct excitation/emission wavelength patterns combined with a reader
equipped with wavelength-speciﬁc ﬁlters prevented bleeding over ef-
fects as shown previously (Janetzki et al., 2014).
3. Results
3.1. FluoroSpot assay using four different antigens
To assess whether multiple antigen-speciﬁc ASCs could be detected
in the FluoroSpot assay, four separate hybridomas producing mAbs
against IFN-γ from four different species were analyzed (Fig. 2). A com-
bination of one biotinylated antigen and three antigens recombinantly
Fig. 2. FluoroSpot analysis of four hybridomas secreting antibodies speciﬁc for different antigens. Four hybridomas raised against interferon-gamma (IFN-γ) from four different species
were incubated in one well (50 cells of each hybridoma per well). The speciﬁcity of the secreted antibodies captured by anti-mouse IgG coating antibody was determined using the
four corresponding antigens labeled with different tags followed by addition of ﬂuorophore-conjugated streptavidin and anti-tag monoclonal antibodies to peptide WASP, GAL and
BAM. A) Well images captured by speciﬁc ﬁlters for each ﬂuorophore as well as a computerized overlay image of the four separate images. Antigens and secondary detection reagents
are indicated below each separate image as is the reader ﬁlter used for the analysis. B) Detailed image of the overlay analysis with blue spots (circle) representing human IFN-γ spots,
green spots (box) representing dog IFN-γ spots, yellow spots (diamond) representing woodchuck IFN-γ spots, and red spots (triangle) representing cow IFN-γ spots. C) Number of
spots counted using the separate ﬁlters. Values are themean of triplicate wells. No spots were counted as double, triple or quadruple positive in the computerized image overlay analysis.
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conjugated SA and anti-tag mAbs respectively, was utilized for the
detection of secreted antibodies. Antibodies, secreted by all four hybrid-
omas could be detected using separate ﬁlter systems for each
ﬂuorophore. Only single positive spots were detected. Analyses using
only one of the antigens and the corresponding detection system in sep-
arate wells, yielded spots detectable only by the relevant ﬁlter (data not
shown). The experiment was repeated three times with different com-
binations of hybridomas and antigens to verify the functionality of the
assay (data not shown).
3.2. FluoroSpot assay for the analysis of cross-reactive ASCs
In addition to being able to analyze ASC reactivity with multiple an-
tigens, the FluoroSpot assay can be used to study cross-reactive antibod-
ies. In themultiplex analysis shown in Fig. 2, although all antigens were
IFN-γ from different species, these species are evolutionarily rather dis-
tant and no cross-reactive ASCs were detected. Two hybridomas raised
against human IL-2 were used to analyze ASCs showing cross-reactivity
(Fig. 3). As shown by ELISA, hybridoma MT2A91 cross-reacted with
rhesus macaque IL-2 but not with sooty mangabey IL-2, whereas hy-
bridoma MT8G10 cross-reacted with IL-2 from both non-human pri-
mate species (Fig. 3A); rhesus macaque and sooty mangabey IL-2
differ only in one amino acid and are 97% identical to human IL-2.
When assessing reactivity with human and sooty mangabey IL-2 in
FluoroSpot, with both hybridomas in the same well, it was conﬁrmed
that only hybridoma MT8G10 cross-reacted with sooty mangabey IL-2
(Fig. 3B–D). Analysis of control wells with single hybridomas and both
antigens yielded double-positive spots with hybridoma MT8G10 but
only single spots with hybridoma MT2A91 (data not shown). When
the hybridomas were analyzed for reactivity with human and rhesusmacaque IL-2, all spots in the wells were double positive as expected
(Fig. 3E–G). However there were differences in the spots generated by
the two hybridomas: MT8G10, which displayed a more comparable re-
activitywith human and rhesusmacaque IL-2, yielded spotswith higher
intensity in the ﬁlter reading rhesus macaque IL-2. As a result, double-
stained spots generated by the two hybridomas were of different colors
in the image overlay analysis; MT8G10-derived spots were yellow-
green whereas MT2A91-derived spots were orange (Fig. 3F).3.3. FluoroSpot assay for the simultaneous determination of ASC antigen-
speciﬁcity and isotype/subclass
A third assay variant was used to address the possibility of deﬁning
the speciﬁcity of antibodies secreted by ASCs while simultaneously de-
termining the isotype/subclass of the antibodies (Fig. 4). The antigen
speciﬁcity of antibodies secreted by two hybridomas was determined
as in the previous assay formats. In the same well, two ﬂuorophore-
conjugated anti-mouse IgG1 and IgG2a mAbs were used for detection.
Spots positive for one antigen were also positive for one IgG subclass
and vice versa. No difference in intensity was observed compared
to spots obtained through detection with antigen alone (data not
shown), demonstrating that detection with IgG subclass-speciﬁc re-
agents does not interfere with the analysis of antigen speciﬁcity; the
subclass-speciﬁc mAbs used bind the Fc domain of the antibodies and
are thus not expected to sterically hinder antigen binding. By blocking
the wells with mouse serum, after ASC-derived antibodies had been
captured and detected with anti-mouse IgG subclass reagents, an anti-
tag detection mAb of mouse IgG1 subclass could be added without
being bound by the anti-mouse IgG1 subclass reagent. This was con-
ﬁrmed by the fact that no anti-mouse IgG1 subclass spots (green spots
Fig. 3. ELISA and FluoroSpot analysis of hybridomas against human interleukin (IL)-2 displaying cross-reactivity with IL-2 from non-human primates. A) ELISA analysis of monoclonal
antibodies (mAbs) from the two hybridomas showing their reactivity with human, sooty mangabey, and rhesus macaque IL-2. B–G) FluoroSpot analysis of two hybridomas raised
against human IL-2. The hybridomas were incubated in the same well (500 cells of hybridoma MT2A91 and 100 cells of hybridoma MT8G10 per well). The speciﬁcity of the secreted
antibodies captured by anti-mouse IgG coating antibody was determined using human IL-2 together with either sooty mangabey or rhesus macaque IL-2 labeled with different tags
(biotin and peptide BAM) followed by the addition of ﬂuorophore-conjugated streptavidin (SA) and mAb anti-BAM. B) Well images show the reactivity with sooty mangabey IL-2 and
human IL-2 as well as a computerized overlay image of the two separate images. Antigens and secondary detection reagents are indicated below each image. C) Detailed image of the
overlay analysis with red spots (circle) representing single positive spots and orange spots (box) representing double positive spots. D) Number of spots counted with separate ﬁlters
and spots co-localized on the different images. Values are the mean of triplicates. E) Same as in B) but utilizing human and rhesus macaque IL-2 for detection. F) Same as in C) but
showing “yellow–green” double positive spots with stronger reactivity with rhesus IL-2 (circle) or orange spots with lower reactivity with rhesus macaque IL-2 (box). G) Same as in
D) but showing the counted spots from the analysis of hybridomas MT8G10 and MT2A91 producing antibodies against human and rhesus macaque IL-2. One of two experiments with
very similar results is shown.
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spots in Fig. 4).
3.4. FluoroSpot assay for the analysis of cross-reactive splenocytes
To demonstrate that the FluoroSpot assay can be applied to cells
other than immortalized hybridomas, splenocytes from amouse immu-
nizedwith cat IFN-γwere analyzed for reactivitywith cat and dog IFN-γ
(87% amino acid sequence identity) (Fig. 5). As the cells were harvested
3 days after the last of four immunizations, no pre-activation of the cells
was necessary. Around 85% of the detected ASCs only showed reactivity
with cat IFN-γwhereas the remaining 15%were cross-reactive and pos-
itive for both cat and dog IFN-γ. When the test was repeated with
splenocytes from the same mouse (with cells that had been harvested
and frozen until use), 14% of the cat IFN-γ-reactive ASC spots demon-
strated cross-reactivity with dog IFN-γ.
4. Discussion
By reversing the classical B-cell ELISpot and instead using soluble an-
tigens labeledwith tags and secondary ﬂuorophore-conjugated anti-tag
reagents for the detection of captured antibodies, the B-cell FluoroSpot
assay offers the possibility of distinguishing ASCs producing antibodies
against multiple antigens in one well. FluoroSpot assays using up to
four different ﬂuorophores were developed and enabled i) the analysis
of ASCs speciﬁc for multiple antigens, ii) the analysis of ASCs displayingcross-reactivity with different but related antigens, and iii) determina-
tion of the antigen-speciﬁcity of ASCs while simultaneously deﬁning
the isotype/subclass of the antibodies secreted.
Compared to the use of ﬂuorescent detection mAbs speciﬁc for the
same antigen as the captured ASC-derived antibodies (Hadjilaou et al.,
2015), the use of tagged antigens and anti-tag detection reagents has
several advantages. Tag systems make it possible to study a variety of
protein antigens, provided the antigens are labeledwith tags. Themeth-
od can thus be easily adapted to measure antibody reactivity in many
situations including antibody responses in infectious diseases, allergy,
and autoimmune disease, and for the monitoring of vaccine responses.
Peptide tags can be coupled to antigens chemically but can also be
added recombinantly which offers the advantages that tags can be
positioned at the N- or C-terminal and that antigens in transfectant su-
pernatants can be used without prior puriﬁcation. The progress of re-
combinant techniques and companies that construct plasmids with
any gene, makes it easy to design and express eukaryotic protein anti-
gens with tags, without much prior experience in the ﬁeld. Similarly,
kits for biotinylation of proteins make such labeling methods easy and
rapid although one has to have the relevant protein in a pure form.
Another beneﬁt of having tags located at the N- or C-terminal is that
anti-tag detection mAbs will not compete for binding to the same epi-
topes that the secreted antibodies potentially recognize. The use of
antigen-speciﬁc mAbs as detection reagents is likely to be effective for
larger antigens with repetitive motifs or virions that present multiple
copies of antigens and hence also multiple epitopes. However, when
Fig. 4. FluoroSpot analysis of antigen speciﬁcity and isotype/subclass of antibodies secreted by two different hybridomas. Two hybridomas raised against interferon-gamma (IFN-γ) from
two different species and secreting antibodies of differentmouse IgG subclasseswere incubated in onewell (100 cells of each hybridoma perwell). Monoclonal antibodies (mAbs) against
mouse IgG1 and IgG2a labeledwith two additional ﬂuorophores were added to determine the IgG subclass of the secreted antibodies captured by anti-mouse IgG coating antibody. In the
samewell, the speciﬁcity of the secreted antibodies was determined using the respective antigens labeled with different tags followed by addition of ﬂuorophore-conjugated streptavidin
(SA) andmAb anti-BAM.A)Well images showing the reactivity of secreted antibodieswith human IFN-γ (405nm) or cow IFN-γ (640nm) aswell as detection bymAbanti-IgG1 (490 nm)
and mAb anti-IgG2a (550 nm). A computerized overlay image of the four separate images is shown (right). B) Detailed image of the overlay analysis with light blue spots (circle)
representing spots double positive for 405 nm and 490 nm and orange spots (box) double positive for 550 nm and 640 nm. C) Number of spots counted using the separate ﬁlters and
spots co-localized on the different ﬁlters. Values are the mean of triplicates. One of two experiments with very similar results is shown.
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substantial risk that a detection antibody reactive to the same antigen as
the ASCs will recognize an epitope already blocked by antibodies de-
rived from ASCs. Smaller protein antigens, such as the cytokines used
as model antigens herein, often elicit antibodies against a limited num-
ber of immunodominant epitope regions (Alfa and Jay, 1988; Kontsek
et al., 1997). The use of an antigen-speciﬁc mAb in the detection step
is therefore likely, in many cases, to compete with antibodies from
ASCs. This was also experimentally conﬁrmed by analyzing hybridomas
that secret antibodies against human IL-2 (unpublished observations).
Captured antibodies secreted by hybridomaMT8G10 could be detected
using human IL-2–BAM followed by addition of mAb MT2A91 but not
mAbMT8G10 or other anti-IL-2 mAbs recognizing the same epitope re-
gion as MT8G10. When hybridoma MT2A91 was used as the ASC, the
situation was reversed. However, anti-BAM mAb detected IL-2–BAM
bound by antibodies secreted by either hybridoma.
Anti-tag antibody binding to tags located at the N- or C-terminal in
an antigen could potentially interfere sterically with antibodies from
ASCs, if these ASC antibodies recognize an epitope that, in the tertiary
structure, is located in the vicinity of a tag. To avoid this potential prob-
lem, a mixture of antigens, labeled at either the N- or the C-terminus
with the same tag, could be used for detection. Chemical biotinylation
of antigens can potentially also lead to blocking of epitopes, if biotin is
conjugated to critical amino acid side chains; however, this can be
avoided by in vitro biotinylation of antigens at either terminus (Li and
Sousa, 2012).
A potential risk of introducing a tag recombinantly is that it inter-
feres with protein folding. However, there are numerous examples offunctional proteins that have been expressed together with fusion part-
ners such as glutathione transferase, Fc regions of antibodies, and vari-
ous peptide tags (Pina et al., 2014). The peptide tags used herein are
similar to His-tags with regard to their size. Comparison of a large num-
ber of proteins, whose structures have been determined, with or with-
out a terminal His-tag, suggests that His-tags generally have very little
impact on protein structure (Carson et al., 2007).
ASCs analyzed by B-cell ELISpot are often memory B cells, pre-
activated for example with R848 and IL-2 in order to secrete antibodies
(Jahnmatz et al., 2013). In cases in which in vivo activated plasmablasts
are present, pre-activation may not be necessary as has been shown
with ASCs after vaccination of humans against swine ﬂu with
Pandemrix™ (Kesa et al., 2012). The mouse splenocytes analyzed here-
in were induced by hyperimmunization and could also be analyzed
without the need for pre-activation. Irrespective of the type of ASCs in-
vestigated, the ability to assess antigen-speciﬁcity of ASCs reactive to
multiple different antigens could be highly relevant within many re-
search areas, not least for studies of infectious diseases and for vaccine
development. Several vaccines currently in use, or undergoing develop-
ment, are composed of multiple proteins from a pathogen (Ocampo
et al., 2014; Xing et al., 2015) or even multiple proteins from different
pathogens (Wang et al., 2015; Zagolski et al., 2015), and a “multiplex”
FluoroSpot assay would enable analysis of B-cell responses to all anti-
gens in onewell. Another beneﬁt is the need for fewer cells for the anal-
ysis which is important for example in studies involving children.
Yet another beneﬁt of being able to analyzemultiple antigens in one
well is that cross-reactivity between antigens can be assessed. Due to
antigenic diversity, immune responses to many pathogens are strain
Fig. 5. FluoroSpot analysis of antigen cross-reactivity displayed by splenocytes from a mouse immunized with cat interferon-gamma (IFN-γ). Splenocytes (500,000 cells/well) from a
mouse immunized with cat IFN-γwere incubated overnight in wells coated with anti-mouse IgG capture antibody. Speciﬁcity of the secreted antibodies was determined using cat and
dog IFN-γ labeled with different tags followed by addition of ﬂuorophore-conjugated streptavidin (SA) and monoclonal antibody (mAb) anti-WASP. A) Well images showing the
reactivity with cat (550 nm) and dog (490 nm) IFN-γ as well as a computerized overlay image of the two separate images. Antigens and secondary detection reagents are indicated
below each image. B) Detailed image of the overlay analysis with red spots (circle) representing single positive spots and orange spots (box) representing double positive spots.
C) Number of spots on the separate images as well as the number of co-localized spots. Values are the mean of triplicates. One of two experiments with very similar results is shown.
29P. Jahnmatz et al. / Journal of Immunological Methods 433 (2016) 23–30speciﬁc and induction of protective immunity may require repeated in-
fections with different strains (Grifﬁn et al., 2015). Some vaccines pres-
ently used, for example against polio virus, papilloma virus, and
pneumococci, are composed of multiple serotypes, and inﬂuenza vac-
cines target the three most prevalent seasonal serotypes (Carrat and
Flahault, 2007; Plosker, 2015; Villa et al., 2007). The same approach is
considered when developing new vaccines, including for malaria and
dengue where the pathogens show antigenic diversity (Osorio et al.,
2011; Riley and Stewart, 2013). The efﬁciencywithwhich vaccines elicit
ASCs producing antibodies with broad reactivity and/or cross-reactivity
with multiple pathogen serotypes or strains could be investigated sim-
ply using the B-cell FluoroSpot assay.
FluoroSpot analysis of ASCs with multiple antigens while simulta-
neously determining the isotype/subclass of the secreted antibodies,
as reported here, has not previously been described. Such assays could
for example be used to assess the balance in human B cells between
the secretion of allergen-reactive IgG4 and IgE antibodies, which is
thought to be relevant for allergic reactions and may be important for
the outcome of allergen-speciﬁc immunotherapy (Savilahti et al.,
2014; Yoo et al., 2014).With further development of the assay, it should
also be possible to assess the character of antigen-speciﬁc immune re-
sponses in terms of the involvement of all different IgG subclasses.
This has been addressed in serological studies of IgG subclass proﬁles
and speciﬁcity toward malaria antigens amongst naturally exposed in-
dividuals (Rouhani et al., 2015), as well as in HIV vaccine research
where studies have shown that vaccine-induced antibodies with the
sameepitope speciﬁcity can elicit different effector functions dependent
on their IgG subclass (Yates et al., 2014).
FluoroSpot assays for cytokines and B cells (using a single
immobilized antigen and detectingmultiple Ig isotypes) have so far uti-
lized up to three ﬂuorophores. Four ﬂuorophores were used for the
antigen-speciﬁc B-cell FluoroSpot presented here. With further devel-
opment of the FluoroSpot assay, for example addition of newﬂuorophores and new tag systems and improved FluoroSpot reader ﬁl-
ters, it is likely that an increased number of antigens could be studied.
An effect of this, however, is that the graphical visualization of spots,
stained by multiple ﬂuorophores, will produce a multitude of colors
that will make it difﬁcult to interpret the images. Nevertheless it should
be noted that the spot color, from an analytical point of view, is irrele-
vant and that the factor determining whether a spot is positive for one
or multiple ﬂuorophores is the position of the spot in each separate
image. The results of the present study also show that the assay can dif-
ferentiate between ASCs with different degrees of cross-reactivity with
an antigen related to the one against which they were raised. The dy-
namic range of ﬂuorophores should, with improved FluoroSpot reader
software, make it possible to deﬁne differences in avidity/afﬁnity be-
tween the reactivity of different ASCs in more detail.
In conclusion, we have demonstrated a new approach for the analy-
sis of single B cells using the FluoroSpot assay together with soluble
tagged antigens that can be adapted to numerous antigens. We believe
that this assay could be a useful tool in various ﬁelds of B-cell research
where information regarding antigen-speciﬁcity, cross-reactivity, or
isotype/subclass is of interest.
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